Preparation and evaluation a new generation of low molecular weight heparin

Biomedicine and Pharmacotherapy

Volumn 79, Issue , 2016, Pages 194-200

  Zhao, Dan ^a   Sang, Qing ^a   Cui, Huifei ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Anti thrombus; Anticoagulation; Low molecular weight heparin (LMWH); Pharmacokinetic; Protamine sulfate; Rational design

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE SULFATE; PROTHROMBIN A; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PROTAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; CAROTID ARTERY THROMBOSIS; CAVA VEIN DISEASE; CONTROLLED STUDY; DEPOLYMERIZATION; DISPERSION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG PURIFICATION; DRUG SCREENING; DRUG SYNTHESIS; ESTERIFICATION; EXPERIMENTAL RABBIT; FEMALE; IN VITRO STUDY; INFERIOR VENA CAVA THROMBOSIS; MALE; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; THROMBOSIS PREVENTION; TIME TO MAXIMUM PLASMA CONCENTRATION; VEIN THROMBOSIS; ANIMAL; CHEMISTRY; DISEASE MODEL; RABBITS AND HARES; SYNTHESIS; WISTAR RAT;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; DISEASE MODELS, ANIMAL; ENOXAPARIN; FACTOR XA INHIBITORS; HEPARIN, LOW-MOLECULAR-WEIGHT; MALE; PROTAMINES; RABBITS; RATS, WISTAR;

EID: 84960362320     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.02.021     Document Type: Article

References (20)

1. Rau J.C., Beaulieu L.M., Huntington J.A., Church F.C. Serpins in thrombosis, hemostasis and fibrinolysis. J. Thromb. Haemost. 2007, 5:102-115.
2. Chakrabarti S., Beaulieu L.M., Reyelt L.A., Iafrati M.D., Freedman J.E. M118, a novel low-molecular weight heparin with decreased polydispersity leads to enhanced anticoagulant activity and thrombotic occlusion in ApoE knockout mice. J. Thrombo. Thrombolysis 2009, 28:394-400.
3. Da Silva M.S., Sobel M. Anticoagulants: To bleed or not to bleed, that is the question. Semin. Vasc. Surg. 2002, 15:256-267.
4. Higashi K., Hosoyama S., Ohno A., Masuko S., Yang B., Sterner E., et al. Photochemical Preparation of a Novel Low Molecular Weight Heparin. Carbohydr. Polym. 2012, 67:1737-1743.
5. Sundaram M., Qi Y., Shriver Z., Liu D., Zhao G., Venkataraman G., et al. Rational design of low-molecular weight heparins with improved in vivo activity. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:651-656.
6. Linhardt R.J., Gunay N.S. Production and chemical processing of low molecular weight heparins. Semin. Thromb. Hemost. 1999, 25:5-16.
7. Petitou M., Imberty A., Duchaussoy P., Driguez P.A., Ceccato M.L., Gourvenec F., et al. Experimental proof for the structure of a thrombin-inhibiting heparin molecule. Chem.-Eur. J 2001, 7:858-873.
8. Toomey J.R., Blackburn M.N., Storer B.L., Valocik R.E., Koster P.F., Feuerstein G.Z. Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosis. Thromb. Res. 2000, 100:73-79.
9. Day J.R.S., Landis R.C., Taylor K.M. Heparin is much more than just an anticoagulant. J. Cardiothorac. Vasc. Anesth. 2004, 18:93-100.
10. Hirsh J., Warkentin T.E., Shaughnessy S.G., Anand S.S., Halperin J.L., Raschke R., et al. Heparin and low-molecular-weight heparin-mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001, 119:64S-94S.
11. Gram J., Mercker S., Bruhn H.D. Does protamine chloride neutralize low molecular weight heparin sufficiently. Thromb. Res. 1988, 52:353-359.
12. D. Roger, Rieux. Mixtures of particular LMWH heparinic polysacchrides for the prophylaxis/treatment of acute thrombotic exents, US, 5389618 [P] (1995).
13. Harenberg J., Kraemer R., Giese C., Marx S., Weiss C., Wehling M. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J. Thromb. Thrombolysis 2011, 32:267-271.
14. Li H., Mao W., Hou Y., Gao Y., Qi X., Zhao C., et al. Preparation, structure and anticoagulant activity of a low molecular weight fraction produced by mild acid hydrolysis of sulfated rhamnan from Monostroma latissimum. Bioresour. Technol. 2012, 114:414-418.
15. Santos J.C., Mesquita J.M., Belmiro C.L., da Silveira C.B., Viskov C., Mourier P.A., et al. Isolation and characterization of a heparin with low antithrombin activity from the body of Styela plicata (Chordata-Tunicata). Distinct effects on venous and arterial models of thrombosis. Thromb. Res. 2007, 121:213-223.
16. Shang J., Chen Z., Wang M., Li Q., Feng W., Wu Y., et al. Zucker Diabetic Fatty rats exhibit hypercoagulability and accelerated thrombus formation in the Arterio-Venous shunt model of thrombosis. Thromb. Res. 2014, 134:433-439.
17. Wang L., Miller C., Swarthout R.F., Rao M., Mackman N., Taubman M.B. Vascular smooth muscle-derived tissue factor is critical for arterial thrombosis after ferric chloride-induced injury. Blood 2009, 113:705-713.
18. Durand E., Helley D., Zen A.A.H., Dujols C., Bruneval P., Colliec-Jouault S., et al. Effect of Low Molecular Weight Fucoidan and Low Molecular Weight Heparin in a Rabbit Model of Arterial Thrombosis. J. Vasc. Res. 2008, 45:529-537.
19. Diaz J.A., Obi A.T., Myers D.D., Wrobleski S.K., Henke P.K., Mackman N., et al. Critical Review of Mouse Models of Venous Thrombosis. Arterioscler. Thromb. Vasc. Biol. 2012, 32:556-562.
20. Von Bruehl M.-L., Stark K., Steinhart A., Chandraratne S., Konrad I., Lorenz M., et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J. Exp. Med. 2012, 209:819-835.